Background: Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis that occurs 2-3 years after an apparently successful treatment of visceral leishmaniasis (VL). In rare cases, PKDL occurs concurrently with VL and is characterized by fever, splenomegaly, hepatomegaly or lymphadenopathy, and poor nutritional status and is known as Para-kala-azar dermal leishmaniasis (Para-KDL). Co-association of active VL in PKDL patients is documented in Africa, but very few case reports are found in South Asia. We present a case of Para-kala-azar Dermal Leishmaniasis (Para-KDL) in a 50-year-old male patient with a history of one primary Visceral Leishmaniasis (VL) and 2 times relapse of Visceral Leishmaniasis (VL). The patient presented with fever, skin lesions, and hepatosplenomegaly. Laboratory tests revealed LD bodies in the slit skin smear and splenic biopsy. The patient was treated with two cycles of Amphotericin B with Miltefosine in between cycles for 12 weeks to obtain full recovery.
Conclusion: This case report serves as a reminder that Para-kala-azar dermal leishmaniasis can develop as a consequence of prior visceral leishmaniasis episodes, even after apparently effective therapy. Since para-kala-azar is a source of infectious spread, endemics cannot be avoided unless it is effectively recognized and treated.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10729440 | PMC |
| http://dx.doi.org/10.1186/s12879-023-08918-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Histopathological Patterns of Cutaneous and Mucocutaneous Leishmaniasis Due to .
Dermatol Res Pract
November 2024
Department of Communicable and Non Communicable Disease, Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
Cutaneous leishmaniasis (CL) is an endemic disease in Ethiopia, mainly caused by . Limited reports are available related to histopathological features of the skin lesion caused by . This study aimed to analyze the histopathological features of CL due to .
View Article and Find Full Text PDFCombination Therapy for Post-Kala-Azar Dermal Leishmaniasis: A Literature Review of Current Evidence.
Indian J Dermatol
October 2024
From the Department of Pharmacology, Lovely Professional University, Phagwara, Punjab, India.
Post-kala-azar dermal leishmaniasis (PKDL) is a neglected skin disease that has tremendous epidemiological significance as a reservoir of Leishmania parasites. Relapse, drug resistance, non-compliance to prolonged treatment, poor health-seeking behaviour, along with limited therapeutic options pose a significant impact on the management of PKDL. In this study, we aimed to review the efficacy, safety and tolerability data of combination therapies for PKDL in the published literature.
View Article and Find Full Text PDFRole of neutrophils in the pathogenesis of Post Kala-azar Dermal Leishmaniasis (PKDL).
PLoS Negl Trop Dis
November 2024
Dept. of Pharmacology, Institute of Post Graduate Medical Education and Research (IPGME&R), Kolkata, India.
Background: Post Kala-azar Dermal Leishmaniasis (PKDL) is a dermal sequel of visceral leishmaniasis (VL), poses a significant threat to the success of ongoing kala-azar elimination program, due to its potential role in sustaining transmission cycles and complicating disease management strategies. In VL, neutrophils have been identified as the 'first line of defence', having multiple roles in disease pathogenesis, but their role in PKDL, if any, still remains elusive; presenting a critical gap in knowledge, and was the aim of this study.
Methodology/principal Findings: In a cohort of PKDL patients, CD66b+ neutrophils were quantified in skin biopsies, followed by immunostaining of FFPE sections to identify activated neutrophils (CD66b+/CD64+) and degranulated (CD66b+/MPO+), along with expression of neutrophil elastase (NE), matrix metalloprotease 9 (MMP9) and collagen I.
Comment on: Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.
J Antimicrob Chemother
November 2024
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Atypical cutaneous leishmaniasis: a new challenge to VL elimination in South-East Asia.
Front Cell Infect Microbiol
November 2024
Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada.
Visceral leishmaniasis (VL) caused by in South-East Asian endemic countries including India, Nepal and Bangladesh has been the primary focus of the ongoing VL elimination program. With a major reduction in VL cases resulting from the elimination program during the last two decades, the efforts are now focused on the challenges posed by potential reservoirs within the asymptomatic cases, HIV-co-infection VL cases and Post Kala-azar Dermal Leishmaniasis (PKDL) cases that continue to sustain the parasite transmission cycle in known and newer endemic zones. This article brings attention to a new potential parasite reservoir in the form of atypical cutaneous leishmaniasis (ACL) cases caused by novel genetic variants.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!